- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04949425
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Enrolled in Adavosertib Clinical Pharmacology Studies
Study Overview
Detailed Description
Patients will be screened within 14 days of Day 1 of the treatment period. During screening, patients will undergo an appropriate washout period after the last dose of adavosertib in the parent clinical pharmacology study before receiving the first dose of adavosertib in this study.
Patients will continue to receive adavosertib as long as they are benefiting from treatment in the investigator's opinion and do not meet any other discontinuation criteria.
The number of patients who enroll is dependent on the number of patients who complete the parent studies, and who tolerate adavosertib in the parent study.
The anticipated total duration of the study is approximately 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom, M20 4BX
- Research Site
-
-
-
-
Texas
-
Dallas, Texas, United States, 75230
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
- Participant has completed one of the parent adavosertib clinical pharmacology studies (i.e., D601HC00004, D601HC00006) and is suitable for continued treatment with adavosertib.
- Eastern Cooperative Oncology Group performance status score of 0 to 1.
- Life expectancy ≥ 12 weeks.
- Participants must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- Males and females of childbearing potential who agree to use contraceptive measures should be consistent with clinical study protocol.
Exclusion Criteria:
- Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade > 2) caused by previous anticancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy.
- Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of adavosertib.
Any significant cardiac diseases currently or within the last 6 months such as:
- unstable angina pectoris
- acute myocardial infarction, congestive heart failure
- conduction abnormality not controlled with pacemaker or medication
- significant ventricular or supraventricular arrhythmias
- Any of the following: History or current evidence of congenital long QT syndrome; concomitant medications known to prolong QT interval or history of medication-related QT prolongation.
- Known to have tested positive for human immunodeficiency virus or active tuberculosis infection.
- Known active hepatitis infection, positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody, at screening.
- Any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant, active infections, and active bleeding diseases) which prohibit participating in the study.
- Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
- Use of an anti-cancer treatment drug ≤ 21 days (≤ 6 weeks for nitroureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib.
- Patient uses drugs that are sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or are moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued 2 weeks or 5 halflives (whichever is longer) prior to Day 1 of dosing.
- Receipt of live virus and live bacterial vaccines whilst the patient is receiving the study intervention and during the 30-day follow-up period. Inactivated vaccines are permitted.
- Currently pregnant (confirmed with positive pregnancy test) or breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with advanced solid tumours
Patients with advanced solid tumours will receive Adavosertib once daily for 5 days followed by 2 days off for 2 weeks out of a 21-day cycle.
|
Patients will receive Adavosertib orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with serious and non-serious adverse events
Time Frame: From screening to safety follow-up (30 days after last dose)
|
Assessment of the safety and tolerability of adavosertib following oral dosing of the capsule formulation in patients with advanced solid tumours
|
From screening to safety follow-up (30 days after last dose)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D601HC00009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the
Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumours
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
EDDC (Experimental Drug Development Centre), A*STAR...ParexelRecruiting
-
RemeGen Co., Ltd.RecruitingAdvanced Solid TumoursChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingAdvanced Solid Tumours
-
AstraZenecaActive, not recruiting
-
Exscientia AI LimitedBiotrialTerminatedAdvanced Solid TumoursFrance, Belgium
-
RemeGen Co., Ltd.Recruiting
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited States, Spain
Clinical Trials on Adavosertib
-
AstraZenecaParexelTerminatedAdvanced Solid TumorsUnited Kingdom
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminated
-
AstraZenecaCompletedAdvanced Solid TumoursJapan
-
Merck Sharp & Dohme LLCCompleted
-
AstraZenecaCompletedOvarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid TumoursUnited States
-
AstraZenecaParexelCompletedUterine Serous CarcinomaUnited States, Italy, Spain, France, Canada
-
Samsung Medical CenterTerminated
-
Samsung Medical CenterCompletedSmall Cell Lung CancerKorea, Republic of